TELYRX HOLDINGS INC. ANNOUNCES COMPLETION OF QUALIFYING TRANSACTION

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

CLEARWATER, Fla. , April 1, 2026 /CNW/ - TelyRx Holdings Inc. ("TelyRx" or the "Resulting Issuer"), formerly Apolo V Acquisition Corp. ("Apolo V"), is pleased to announce that it has completed the previously announced qualifying transaction (the "Transaction") with TelyRx, Inc. and TelyRx Finco Inc. ("TelyRx Finco"), among others, which constituted Apolo V's Qualifying Transaction, as such term is defined under the policies of the TSX Venture Exchange (the "TSXV").

In connection with the Transaction, Apolo V changed its name to TelyRx Holdings Inc., consolidated its common shares on a basis of one post consolidated common share for every 30 pre-consolidated common shares and amended its share capital such that the common shares of Apolo V are now known as subordinate voting shares ("SVS") and an additional class of shares, known as proportionate voting shares ("PVS"), was created.

Prior to the completion of the Transaction, TelyRx Finco completed a brokered private placement of 7,980,260 subscription receipts ("Subscription Receipts") for aggregate gross proceeds of $35,911,170 (the "Private Placement"). Canaccord Genuity Corp. ("Canaccord") acted as lead agent and sole bookrunner in connection with the Private Placement, on behalf of a syndicate of agents including ATB Capital Markets Corp., Clarus Securities, Inc. and Raymond James Ltd. (collectively with Canaccord, the "Agents"). The Private Placement was conducted pursuant to an agency agreement dated March 26, 2026 among the Agents, TelyRx, TelyRx, Inc. and TelyRx Finco. Each Subscription Receipt was convertible, upon satisfaction of certain escrow release conditions set out in the subscription receipt agreement governing the Subscription Receipts, into one common share of TelyRx Finco.

As part of the Transaction, a wholly-owned subsidiary of Apolo V merged with and into TelyRx, Inc. and the shareholders of TelyRx, Inc. became shareholders of the Resulting Issuer, receiving SVS and/or PVS, with the allocation determined in accordance with their jurisdiction of residence.  Additionally, another wholly-owned subsidiary of Apolo V amalgamated with TelyRx Finco and the shareholders of TelyRx Finco (the investors in the Private Placement) received SVS of the Resulting Issuer on a one-for-one basis.

TelyRx has received conditional approval of the listing of the SVS on the Toronto Stock Exchange (the "TSX") under ticker symbol "TELY". Final approval is subject to TelyRx ‎meeting certain customary conditions required by the TSX. TelyRx will issue a press release once ‎the TSX confirms the date when trading of the SVS is expected to commence on the TSX.

Immediately following completion of the Transaction, the directors and officers of Apolo V resigned and were replaced by the directors and officers set out in the filing statement of Apolo V dated March 24, 2026.

For additional information about TelyRx and the transaction, please refer to the filing statement which has been filed on TelyRx's profile on SEDAR+.

ABOUT TELYRX

TelyRx is a technology-enabled healthcare and pharmacy services company operating a digital pharmacy platform. Connecting patients with independent, state-licensed providers to access over 350 everyday medications across 48 U.S. states and territories, the company fulfills prescriptions through licensed retail pharmacies in Florida and Texas, delivering essential medication directly with no friction, no delays, and no barriers.

FORWARD-LOOKING STATEMENTS

This press release contains certain forward-looking statements, including but not limited to statements about the listing of the SVS of TelyRx on the TSX and the timing thereof. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. 

Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, TelyRx cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and TelyRx does not assume an obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Investors are cautioned that, except as disclosed in the Filing Statement filed by Apolo V, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

The TSXV has in no way passed upon the merits of the Transaction and has neither approved nor disapproved the contents of this press release.

SOURCE TelyRx Holdings Inc.

For further information regarding TelyRx: Neil Weber, Telephone: [phone], E-mail: [email protected]